Indication

Muscle weakness in Barth syndrome

Muscle weakness in Barth syndrome is a clinical manifestation of the underlying skeletal myopathy that characteristically affects hemizygous males with this rare, X-linked mitochondrial condition. Read more about Muscle weakness in Barth syndrome

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Muscle weakness in Barth syndrome therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Muscle weakness in Barth syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Muscle weakness in Barth syndrome.

Muscle weakness in Barth syndrome is a clinical manifestation of the underlying skeletal myopathy that characteristically affects hemizygous males with this rare, X-linked mitochondrial condition.

Pathophysiologically, it stems from pathogenic variants in the *TAFAZZIN* gene, which disrupt cardiolipin remodeling in the inner mitochondrial membrane, impairing cellular respiratory chain function and skeletal muscle bioenergetics.

Clinically, affected individuals typically demonstrate generalized hypotonia from infancy, reduced muscle bulk, and predominantly proximal muscle weakness.

This impairment contributes to delayed early motor milestone achievement, diminished physical stamina, and severe exercise intolerance that persists into adulthood.

Personalize your experience

Follow Muscle weakness in Barth syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it